PBM Module 3 Evidence-tabel
Evidence table for intervention studies (randomized controlled trials and non-randomized observational studies [cohort studies, case-control studies, case series])
Study reference |
Study characteristics |
Patient characteristics |
Intervention (I) |
Comparison / control (C) |
Follow-up |
Outcome measures and effect size |
---|---|---|---|---|---|---|
Alhmidi & Cadnum (2021) |
Type of study: observational Setting and country: medical-surgical ward, USA Funding and conflicts of interest: funded by Centers for Disease Control and Prevention Conflicts of interest: no |
Inclusion criteria: Exclusion criteria: N total at baseline: Important prognostic factors: Groups comparable at baseline? |
Describe intervention (treatment / procedure / test): In total, 30 source patients had 1 cauliflower mosaic virus surrogate marker applied to their skin and clothing and a second to their bed rail and bedside table. Personnel caring for the source patients were randomized to wear: |
Describe control (treatment / procedure / test): No barrier |
Length of follow-up: |
Outcome measures and effect size (include 95%CI and p-value if available): No barrier Gloves Gloves plus gown |
Alhmidi & Li (2021) |
Type of study: observational Setting and country: Funding and conflicts of interest: |
Inclusion criteria: Exclusion criteria: N total at baseline: |
Describe intervention (treatment / procedure / test): personnel each performed 3 standardized examinations of mannequins contaminated with pathogen surrogate markers while wearing: |
Describe control (treatment / procedure / test): personnel each performed 3 standardized examinations of mannequins contaminated with pathogen surrogate markers while wearing no barriers |
Length of follow-up: Loss-to-follow-up: Incomplete outcome data: |
Outcome measures and effect size (include 95%CI and p-value if available): Transfer by hands Transfer by stethoscope: To environment |
Harris (2021) |
Type of study: RCT (cluster randomized) Setting and country: intensive care unit, USA Funding and conflicts of interest: AHRQ |
Inclusion criteria: Exclusion criteria: N total at baseline: Important prognostic factors: |
Describe intervention (treatment / procedure / test): All healthcare workers were required to wear gloves and gowns for all patient contact and when entering any patient room |
Describe control (treatment / procedure / test): Usual care |
Length of follow-up: Loss-to-follow-up: Incomplete outcome data: |
Outcome measures and effect size (include 95%CI and p-value if available): acquisition of any antibiotic-resistant gram-negative bacteria: RR 0.90 (95% CI, .71–1.12; P = .34) carbapenem-resistant Enterobacteriaceae RR, 0.86 [95% CI, .60–1.24; P = .43 carbapenemresistant Acinetobacter RR, 0.81 [95% CI, .52–1.27; P = .36 carbapenem-resistant Pseudomonas RR, 0.88 [95% CI, .55–1.42]; P = .62 extended-spectrum β-lactamase–producing bacteria (RR, 0.94 [95% CI, .71–1.24]; P = 0.67). |
Chang (2019) |
See paper |
|
|
|
|
|
Webster (2015) | See paper |